Reports related to this article:
Project(s): View 3 related projects in PECWeb
Plant(s): View 3 related plants in PECWeb
Released August 20, 2014 | SUGAR LAND
en
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--Midway through the third quarter of 2014, the Pharmaceutical-Biotech Industry is busy finishing an impressive array of capital construction projects. With roughly a month and a half left to the quarter, the sector is on target to complete construction on a total of 156 North American capital projects, each as diverse as the industry itself. A recent survey of reported projects in Industrial Info's Pharmaceutical Tracker - Online Database reveals that the projects represent a total investment value (TIV) of $1.3 billion.
Click on the image at right for a graph detailing North American Pharmaceutical-Biotech Projects to be completed in third-quarter 2014 by region.
Sources for the third-quarter activity include private industry, commercial developers, universities and the federal government. The projects reported involve grassroot facilities, major building additions to existing sites, and in-plant capital. The projects are a varied group in both size and focus. The average TIV for each of the projects is a healthy $8.2 million.
The largest of the projects scheduled for third-quarter completion is the $200 million Genzyme upgrade/renovation project in Allston, Massachusetts. With a project team that includes project manager Taurus Project Controls (Andover, Massachusetts), CRB Consulting Engineers (Plymouth, Massachusetts) and Turner Construction (Boston, Massachusetts), the massive renovation project began in 2012. Originally known as "Project Rena," Genzyme renovated and upfit approximately 50,000 to 75,000 square feet within the existing 300,000-square-foot plant, including a complete renovation of harvest, media and buffer prep areas, the construction of a new quality control lab, and the conversion of former fill/finish areas to mammalian cell culture space.
View Plant Report - 1014714
View Project Report - 300128159
In Sainte-Foy, Quebec, GlaxoSmithKline (NYSE:GSK) is wrapping up a $90 million fill and finish expansion of its influenza vaccine plant. Verreault Construction (Quebec City, Quebec) upgraded and expanded the filling and finishing to double capacity to 30 million units per year, while decreasing delivery time. NFOE Architects (Montreal, Quebec) was part of the project team.
View Plant Profile - 1025527
View Project Report - 200002607
Ipsen Biosciences (Cambridge, Massachusetts) recently completed a $35 million project that built-out 62,000 square feet of leased space with Biomed Realty Trust's (Cambridge) 280,000-square-foot building at 650 East Kendall Square in Cambridge. The new location will offer complete research and development laboratories for peptides and proteins, along with housing the new company headquarters. Consigli Construction Company Incorporated (Milford, Massachusetts) was the project contractor.
View Plant Profile - 3103217
View Project Report - 300137189
From a regional standpoint, New England will have completed the most projects with the highest TIV, having finished 12 valued at $300 million during the third quarter of 2014. Next up is the Northeast, with 13 projects valued at $217 million. The Great Lakes rounds out the top three with $131 million invested in 12 projects. The remaining activity is scattered across North America.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, three offices in North America and 10 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities.
Click on the image at right for a graph detailing North American Pharmaceutical-Biotech Projects to be completed in third-quarter 2014 by region.Sources for the third-quarter activity include private industry, commercial developers, universities and the federal government. The projects reported involve grassroot facilities, major building additions to existing sites, and in-plant capital. The projects are a varied group in both size and focus. The average TIV for each of the projects is a healthy $8.2 million.
The largest of the projects scheduled for third-quarter completion is the $200 million Genzyme upgrade/renovation project in Allston, Massachusetts. With a project team that includes project manager Taurus Project Controls (Andover, Massachusetts), CRB Consulting Engineers (Plymouth, Massachusetts) and Turner Construction (Boston, Massachusetts), the massive renovation project began in 2012. Originally known as "Project Rena," Genzyme renovated and upfit approximately 50,000 to 75,000 square feet within the existing 300,000-square-foot plant, including a complete renovation of harvest, media and buffer prep areas, the construction of a new quality control lab, and the conversion of former fill/finish areas to mammalian cell culture space.
View Plant Report - 1014714
View Project Report - 300128159
In Sainte-Foy, Quebec, GlaxoSmithKline (NYSE:GSK) is wrapping up a $90 million fill and finish expansion of its influenza vaccine plant. Verreault Construction (Quebec City, Quebec) upgraded and expanded the filling and finishing to double capacity to 30 million units per year, while decreasing delivery time. NFOE Architects (Montreal, Quebec) was part of the project team.
View Plant Profile - 1025527
View Project Report - 200002607
Ipsen Biosciences (Cambridge, Massachusetts) recently completed a $35 million project that built-out 62,000 square feet of leased space with Biomed Realty Trust's (Cambridge) 280,000-square-foot building at 650 East Kendall Square in Cambridge. The new location will offer complete research and development laboratories for peptides and proteins, along with housing the new company headquarters. Consigli Construction Company Incorporated (Milford, Massachusetts) was the project contractor.
View Plant Profile - 3103217
View Project Report - 300137189
From a regional standpoint, New England will have completed the most projects with the highest TIV, having finished 12 valued at $300 million during the third quarter of 2014. Next up is the Northeast, with 13 projects valued at $217 million. The Great Lakes rounds out the top three with $131 million invested in 12 projects. The remaining activity is scattered across North America.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, three offices in North America and 10 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities.
